Ipsen SA (IPNp)

BATS Europe
Currency in EUR
104.10
0.00(0.00%)
Closed·
IPNp Scorecard
Full Analysis
Net income is expected to grow this year
IPNp is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
104.10104.40
52 wk Range
90.43123.30
Key Statistics
Edit
Bid/Ask
110.40 / 111.90
Prev. Close
104.1
Open
104.4
Day's Range
104.1-104.4
52 wk Range
90.43-123.3
Volume
25
Average Vol. (3m)
212
1-Year Change
-14.39%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPNp Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Ipsen SA News & Analysis

Show more

Ipsen SA Company Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Employees
5358
Market
France

Compare IPNp to Peers and Sector

Metrics to compare
IPNp
Peers
Sector
Relationship
P/E Ratio
24.0x23.8x−0.5x
PEG Ratio
−0.520.140.00
Price / Book
2.0x3.5x2.6x
Price / LTM Sales
2.4x3.0x3.1x
Upside (Analyst Target)
-3.0%51.1%
Fair Value Upside
Unlock14.4%8.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.30%
Dividend Yield
1.35%
Industry Median 1.19%
Annualized Payout
1.40
Paid annually
5-Years Growth
+6.96%
Growth Streak

Earnings

Latest Release
Apr 16, 2025
EPS / Forecast
1.37 / --
Revenue / Forecast
918.80M / 807.84M
EPS Revisions
Last 90 days

IPNp Income Statement

People Also Watch

120.60
BIOX
-1.55%
25.42
EDEN
-2.46%
28.24
SCOR
-0.28%
55.50
EXHO
-0.36%
29.36
RUBF
0.00%

FAQ

What Is the Ipsen SA (IPNp) Stock Price Today?

The Ipsen SA stock price today is 104.10

What Stock Exchange Does Ipsen SA Trade On?

Ipsen SA is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Ipsen SA?

The stock symbol for Ipsen SA is "IPNp."

Does Ipsen SA Pay Dividends? What’s The Current Dividend Yield?

The Ipsen SA dividend yield is 1.35%.

What Is the Ipsen SA Market Cap?

As of today, Ipsen SA market cap is 8.54B.

What Is Ipsen SA's Earnings Per Share (TTM)?

The Ipsen SA EPS (TTM) is 4.30.

When Is the Next Ipsen SA Earnings Date?

Ipsen SA will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is IPNp a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Ipsen SA Stock Split?

Ipsen SA has split 0 times.

How Many Employees Does Ipsen SA Have?

Ipsen SA has 5358 employees.

What is the current trading status of Ipsen SA (IPNp)?

As of Jun 16, 2025, Ipsen SA (IPNp) is trading at a price of 104.10, with a previous close of 104.10. The stock has fluctuated within a day range of 104.10 to 104.40, while its 52-week range spans from 90.43 to 123.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.